噬菌体抗肺炎克雷伯菌感染及其临床应用的研究进展

doi:10.16431/j.cnki.1671-7236.2025.06.047

摘要/Abstract

摘要： 肺炎克雷伯菌(Klebsiella pneumoniae，KP)是一种重要的人兽共患致病菌，可引发多种感染，严重影响人类和动物健康。多重耐药KP的广泛传播及高毒力肺炎克雷伯菌(hvKP)的蔓延引起人们对KP感染的重点关注。抗生素是抗KP感染的重要手段，但随着抗生素耐药性(AMR)的出现及多重耐药性加剧，抗生素治疗已无法满足临床需求。噬菌体疗法因其独特抗菌机制而备受关注，有研究表明，噬菌体能够有效抗KP感染，但目前相关报道主要集中在临床前体内、体外试验及少量临床案例中，缺乏系统性的安全性评价及应用指导。笔者总结了国内外现有研究数据，系统性回顾了噬菌体抗KP感染的临床前研究和临床病例报告，旨在为开发抗KP感染的噬菌体治疗方案提供参考。

关键词: 肺炎克雷伯菌(KP); 噬菌体; 抗感染; 临床应用

Abstract: Klebsiella pneumoniae (KP) is a significant zoonotic pathogen that can cause various infections,impacting the health of both humans and animals.The widespread spread of multidrug-resistant KP and the spread of highly virulent KP (hvKP) have aroused great concern for KP infection.Antibiotics are a crucial means to combat KP infection,but the emergence of antimicrobial resistance (AMR) and the exacerbation of multidrug resistance have rendered antibiotic treatment insufficient to meet clinical needs.Phage therapy has attracted much attention due to its unique antibacterial mechanism.Studies have shown that phage can effectively fight KP infection.However,relevant reports mainly focus on pre-clinical in vivo and in vitro trials and a few clinical cases,and lack systematic safety evaluation and application guidance.The author summarized the existing research data from domestic and international studies,systematically reviewed the preclinical studies and clinical case reports of phage against KP infection,aiming to provide reference for the development of phage therapy against KP infection.

Key words: Klebsiella pneumoniae (KP); phage; anti-infection; clinical application

中图分类号:

S852.61⁺2

张玉莹, 邢家宝, 张一超, 张航, 张俊锴, 翟亚军, 赵金鑫, 吴华. 噬菌体抗肺炎克雷伯菌感染及其临床应用的研究进展[J]. 中国畜牧兽医, 2025, 52(6): 2955-2964.

ZHANG Yuying, XING Jiabao, ZHANG Yichao, ZHANG Hang, ZHANG Junkai, ZHAI Yajun, ZHAO Jinxin, WU Hua. Research Progress on Phage Against Klebsiella pneumoniae Infection and Clinical Application[J]. China Animal Husbandry & Veterinary Medicine, 2025, 52(6): 2955-2964.

参考文献

[1] AGGARWAL R,MAHAJAN P,PANDIYA S,et al.Antibiotic resistance:A global crisis,problems and solutions[J]. Critical Reviews in Microbiology,2024,50(5):896-921.
[2] 翟若南,吴安华.世界卫生组织《2024年细菌类重点病原体目录》[J].中国感染控制杂志,2024,23(6):782-783.ZHAI R N,WU A H.World Health Organization bacterial priority pathogens list,2024[J].Chinese Journal of Infection Control,2024,23(6):782-783.(in Chinese)
[3] ASOKAN G V,RAMADHAN T,AHMED E,et al.WHO global priority pathogens list:A bibliometric analysis of Medline-Pubmed for knowledge mobilization to infection prevention and control practices in Bahrain[J]. Oman Medical Journal,2019,34(3):184-193.
[4] 孔祥宇,杨文静,庞申雨,等.肺炎克雷伯菌噬菌体分离鉴定及抑菌效果研究[J].中国农业大学学报,2024,29(9):102-111.KONG X Y,YANG W J,PANG S Y,et al.Isolation,identification,and antibacterial effect of bacteriophages against Klebsiella pneumoniae[J].Journal of China Agricultural University,2024,29(9):102-111.(in Chinese)
[5] V VOLOZHANTSEV N,M SHPIRT A,I BORZILOV A,et al.Characterization and therapeutic potential of bacteriophage-encoded polysaccharide depolymerases with β galactosidase activity against Klebsiella pneumoniae K57 capsular type[J].Antibiotics,2020,9(11):732.
[6] 王靖,杨永芳,杨丽芳,等.鲍氏不动杆菌噬菌体研究进展[J].中华医院感染学杂志,2024,17:2709-2714.WANG J,YANG Y F,YANG L F,et al.Research progress on bacteriophages against Acinetobacter baumannii[J].Chinese Journal of Nosocomiology,2024,17:2709-2714.(in Chinese)
[7] STRAUB M E,APPLEBAUM M.Studies on commercial bacteriophage products[J].The Journal of the American Medical Association,1933,100：110-113.
[8] 涵宇,曹玲,甘霖,等.噬菌体治疗多重耐药细菌感染性肺炎的应用现状[J].中国药学杂志,2024,59(6):549-554.HAN Y,CAO L,GAN L,et al.Application progress of bacteriophage in the treatment of multidrug-resistant bacterial pneumonia[J].Chinese Pharmaceutical Journal,2024,59(6):549-554.(in Chinese)
[9] SMITH H W，HUGGINS M B.Successful treatment of experimental Escherichia coli infections in mice using phage:Its general superiority over antibiotics[J]. Journal of General and Applied Microbiology,1982,128(2):307-318.
[10] RYSZARD M,HOYLE N,ZHVANIYA F，et al.Current updates from the long-standing phage research centers in Georgia,Poland,and Russia[J].Bacteriophages:Biology,Technology,Therapy,2018.Doi:10.1007/978-3-319-40598-8_31-1.
[11] FAUCONNIER A.Phage therapy regulation:From night to dawn[J].Viruses,2019,11(4):352.
[12] GARWOOD K.The perfect predator:A scientist’s race to save her husband from a deadly superbug[J].Perspectives on Science and Christian Faith,2020,72(4):249-252.
[13] 舒飞鸿,王达利,黄广涛.不同给药途径在噬菌体治疗中的研究进展[J].重庆医学,2022,51(21):3743-3749.SHU F H,WANG D L,HUANG G T.Research progress of different administration routes of bacteriophage therapy[J].Chongqing Medical Journal,2022,51(21):3743-3749.(in Chinese)
[14] EFSA PANEL ON BIOLOGICAL HAZARDS (BIOHAZ).Evaluation of the safety and efficacy of Listex^TM P100 for reduction of pathogens on different ready-to-eat (RTE) food products[J].EFSA Journal, 2016,14(8):e04565.
[15] 郭文洁,高丹,王若琪,等.噬菌体疗法在动物细菌感染中的应用研究进展[J].黑龙江畜牧兽医,2023,20:29-34.GUO W J,GAO D,WANG R Q,et al.Research progress on the application of phage therapy in bacterial infections in animals[J].Heilongjiang Animal Science and Veterinary Medicine,2023,20:29-34.(in Chinese)
[16] 赵晓明,夏露,王晓旭,等.应用噬菌体喷雾消毒剂防控细菌性奶牛乳腺炎[J].中国抗生素杂志,2024,49(10):1192-1201.ZHAO X M,XIA L,WANG X X,et al.Application of bacteriophage spray disinfectant for the prevention and control of bacterial mastitis in dairy cows[J].Chinese Journal of Antibiotics,2024,49(10):1192-1201.(in Chinese)
[17] 安瑞.噬菌体治疗的前世、今生与未来—对话微生物学界噬菌体专家[J].科学通报,2017,62(23):2577-2580.AN R.The past,present and future of phage therapy:A dialogue with phage experts in the field of microbiology[J].Chinese Science Bulletin,2017,62(23):2577-2580.(in Chinese)
[18] LIANG S,QI Y,YU H,et al.Bacteriophage therapy as an application for bacterial infection in China[J].Antibiotics (Basel,Switzerland),2023,12(2):417.
[19] YANG Q,LE S,ZHU T,et al.Regulations of phage therapy across the world[J].Frontiers in Microbiology,2023,14:1250848.
[20] 中国噬菌体研究联盟,中国生物工程学会噬菌体技术专业委员会,中国微生物学会医学微生物学与免疫学专业委员会.噬菌体治疗中国专家建议[J].中华传染病杂志,2023,41(10):631-639.CHINA PHAGE RESEARCH ALLIANCE,PHAGE TECHNOLOGY PROFESSIONAL COMMITTEE OF CHINESE SOCIETY OF BIOENGINEERING,MEDICAL MICROBIOLOGY AND IMMUNOLOGY PROFESSIONAL COMMITTEE OF CHINESE SOCIETY FOR MICROBIOLOGY.Expert recommendations on phage therapy in China[J]. Chinese Journal of Infectious Diseases,2023,41(10):631-639.(in Chinese)
[21] 中华医学会器官移植学分会.中国肾脏移植受者细菌感染临床诊疗指南(2023版)[J].中华器官移植杂志，2024，45:1-12.CHINESE SOCIETY OF ORGAN TRANSPLANTATION,CHINESE MEDICAL ASSOCIATION.Clinical practice guidelines for bacterial infections in kidney transplant recipients in China (2023 edition)[J].Chinese Journal of Organ Transplantation,2024,45:1-12.(in Chinese)
[22] 秦金红,郭晓奎,吴楠楠,等.预防及治疗用噬菌体质量标准专家共识[J].中国生物工程杂志,2024,44(1):152-158.QIN J H,GUO X K,WU N N,et al.Expert consensus on quality standards for bacteriophages used in prevention and treatment[J].China Biotechnology,2024,44(1):152-158.(in Chinese)
[23] 王晓明,张涛.中国首个临床治疗用噬菌体制剂质量要求团体标准的发布[J].中华药学杂志,2024,45(8):1321-1325.WANG X M,ZHANG T.Publication of China’s first group standard for quality requirements of clinical therapeutic bacteriophage preparations[J].Chinese Pharmaceutical Journal,2024,45(8):1321-1325.(in Chinese)
[24] LIU R,HAN G,LI Z,et al.Bacteriophage therapy in aquaculture:Current status and future challenges[J].Folia Microbiologica,2022,67(4):573-590.
[25] 满成,徐士杰,苑慧欣,等.一株犬源Ackermannviridae噬菌体LHE287生物学特性和全基因组序列分析[J].中国生物工程杂志,2024,44(8):27-35.MAN C,XU S J,YUAN H X,et al.Biological characteristics and whole genome sequence analysis of a canine-derived Ackermannviridae phage LHE287[J].China Biotechnology,2024,44(8):27-35.(in Chinese)
[26] 张勇超,田苗苗,王思寒,等.宠物常见细菌性疾病及其防治研究进展[J].广东畜牧兽医科技,2022,47(3):112-117.ZHANG Y C,TIAN M M,WANG S H,et al.Research progress in the prevention and control methods of common bacterial diseases in pets[J].Guangdong Journal of Animal and Veterinary Sciences,2022,47(3):112-117.(in Chinese)
[27] 青岛市工业和信息化局.青岛诺安百特噬菌体产品获FDA GRAS认可[EB/OL].[2024-11-20].https://gxj.qingdao.gov.cn/swyycy/202406/t20240624_8094734.shtml.QINGDAO MUNICIPAL BUREAU OF INDUSTRY AND INFORMATION TECHNOLOGY.Qingdao Nuoanbacter phage product obtained GRAS approval from FDA[EB/OL].[2024-11-20].https://gxj.qingdao.gov.cn/swyycy/202406/t20240624_8094734.shtml.(in Chinese)
[28] FOOD AND DRUG ADMINISTRATION (FDA).Animal & veterinary[EB/OL].[2024-11-14].https://www.fda.gov/animal-veterinary
[29] HATFULL G F,DEDRICK R M，SCHOOLEY R T.Phage therapy for antibiotic-resistant bacterial infections[J].Annual Review of Medicine,2022,73:197-211.
[30] ZAKI B M,FAHMY N A,AZIZ R K,et al.Characterization and comprehensive genome analysis of novel bacteriophage,vB_Kpn_ZCKp20p,with lytic and anti-biofilm potential against clinical multidrug-resistant Klebsiella pneumoniae[J].Frontiers in Cellular and Infection Microbiology,2023,13:1077995.
[31] CHEN X Y,TANG Q,LI X,et al.Isolation,characterization,and genome analysis of bacteriophage P929 that could specifically lyase the KL19 capsular type of Klebsiella pneumoniae[J].Virus Research,2022,314:198750.
[32] AL-MADBOLY L A,ABDELAZIZ A A,ABO-KAMER A M,et al.Characterization and genomic analysis of novel bacteriophage NK20 to revert colistin resistance and combat pandrug-resistant Klebsiella pneumoniae in a rat respiratory infection model[J].Life Sciences,2023,322:121639.
[33] FANG Q,FENG Y,MCNALLY A,et al.Characterization of phage resistance and phages capable of intestinal decolonization of carbapenem-resistant Klebsiella pneumoniae in mice[J].Communications Biology,2022,5(1):48.
[34] LI J H,YAN B,HE B,et al.Development of phage resistance in multidrug-resistant Klebsiella pneumoniae is associated with reduced virulence:A case report of a personalised phage therapy[J].Clinical Microbiology and Infection,2023,29(12):1601.e1-1601.e7.
[35] VERMA V,HARJAI K,CHHIBBER S.Restricting ciprofloxacin-induced resistant variant formation in biofilm of Klebsiella pneumoniae B5055 by complementary bacteriophage treatment[J].The Journal of Antimicrobial Chemotherapy,2009,64(6):1212-1218.
[36] PACIOS O,FERNÁNDEZ-GARCÁA L,BLERIOT I,et al.Enhanced antibacterial activity of repurposed mitomycin C and imipenem in combination with the lytic phage vb_kpnm-vac13 against clinical isolates of Klebsiella pneumoniae[J].Antimicrobial Agents and Chemotherapy，2021,65(9):e0090021.
[37] HODYRA-STEFANIAK K,MIERNIKIEWICZ P,DRAPAŁA J.et al.Mammalian host-versus-phage immune response determines phage fate in vivo[J].Scientific Reports, 2015,5:14802.
[38] JO AŃG CZYK E,KŁAK M,MIDZYBRODZKI R,et al.The influence of external factors on bacteriophages—Review[J].Folia Microbiologica,2011,56(3):191-200.
[39] DBROWSKA K.Phage therapy:What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review[J].Medicinal Research Reviews,2019,39(5):2000-2025.
[40] DHUNGANA G,NEPAL R,REGMI M,et al.Pharmacokinetics and pharmacodynamics of a novel virulent Klebsiella phage Kp_Pokalde_002 in a mouse model[J].Frontiers in Cellular and Infection Microbiology,2021,11:684704.
[41] BAI J,ZHANG F,LIANG S,et al.Isolation and characterization of vB_kpnM_17-11,a novel phage efficient against carbapenem-resistant Klebsiella pneumoniae[J].Frontiers in Cellular and Infection Microbiology,2022,12:897531.
[42] CUI X,DU B,FENG J,et al.A novel phage carrying capsule depolymerase effectively relieves pneumonia caused by multidrug-resistant Klebsiella aerogenes[J].Journal of Biomedical Science,2023,30(1):75.
[43] GAN L,FENG Y,DU B,et al.Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae[J].Nature Communications,2023,14(1):3215.
[44] VOLOZHANTSEV N V,BORZILOV A I,SHPIRT A M,et al.Comparison of the therapeutic potential of bacteriophage KpV74 and phage-derived depolymerase (β-glucosidase) against Klebsiella pneumoniae capsular type K2[J]. Virus Research,2022,322:198951.
[45] CHHIBBER S,KAUR S，KUMARI S.Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice[J].Journal of Medical Microbiology,2008,57(Pt 12):1508-1513.
[46] WANG Z J,CAI R,WANG G,et al.Combination therapy of phage Vb_KpnM_P-KP2 and gentamicin combats acute pneumonia caused by k47 serotype Klebsiella pneumoniae[J].Frontiers in Microbiology,2021,12:674068.
[47] GU J,LIU X,LI Y,et al.A method for generation phage cocktail with great therapeutic potential[J].Public Library of Science One, 2012,7(3):e31698.
[48] SONG L,YANG X,HUANG J,et al.Phage selective pressure reduces virulence of hypervirulent Klebsiella pneumoniae through mutation of the wzc gene[J].Frontiers in Microbiology,2021,12:739319.
[49] FENG J,LI F,SUN L,et al.Characterization and genome analysis of phage vB_KpnS_SXFY507 against Klebsiella pneumoniae and efficacy assessment in Galleria mellonella larvae[J].Frontiers in Microbiology,2023,14:1081715.
[50] WINTACHAI P,NAKNAEN A,THAMMAPHET J,et al.Characterization of extended-spectrum-β-lactamase producing Klebsiella pneumoniae phage KP1801 and evaluation of therapeutic efficacy in vitro and in vivo[J].Scientific Reports,2020,10(1):11803.
[51] MARTINS W,LI M,SANDS K,et al.Effective phage cocktail to combat the rising incidence of extensively drug-resistant Klebsiella pneumoniae sequence type 16[J].Emerging Microbes & Infections,2022,11(1):1015-1023.
[52] FLETCHER J,MANLEY R,FITCH C,et al.The citizen phage library:Rapid isolation of phages for the treatment of antibiotic resistant infections in the UK[J].Microorganisms,2024,12(2):253.
[53] ASSAFIRI O,SONG A A,TAN G H,et al.Klebsiella virus UPM2146 lyses multiple drug-resistant Klebsiella pneumoniae in vitro and in vivo[J]. Public Library of Science One,2021,16(1):e0245354.
[54] SUNDARAMOORTHY N S,THOTHATHRI S,BHASKARAN M,et al.Phages from ganges river curtail in vitro biofilms and planktonic growth of drug resistant Klebsiella pneumoniae in a zebrafish infection model[J].AMB Express,2021,11(1):27.
[55] ASTELL K R，SIEGER D.Zebrafish in vivo models of cancer and metastasis[J].Cold Spring Harbor Perspectives in Medicine,2020,10(8):a037077.
[56] ARCHANA A,PATEL P S,KUMAR R,et al.Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model[J].Indian Journal of Virology,2021,32(1):38-45.
[57] MANOHAR P,LOH B,ELANGOVAN N,et al.A multiwell-plate caenorhabditis elegans assay for assessing the therapeutic potential of bacteriophages against clinical pathogens[J].Microbiology Spectrum,2022,10(1):e0139321.
[58] LE T,NANG S C,ZHAO J,et al.Therapeutic potential of intravenous phage as standalone therapy for recurrent drug-resistant urinary tract infections[J]. Antimicrobial Agents and Chemotherapy,2023,67(4):e0003723.
[59] QIN J,WU N,BAO J,et al.Heterogeneous Klebsiella pneumoniae co-infections complicate personalized bacteriophage therapy[J].Frontiers in Cellular and Infection Microbiology,2020,10:608402.
[60] BAO J,WU N,ZENG Y,et al.Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae[J]. Emerging Microbes & Infections,2020,9(1):771-774.
[61] RUBALSKII E,RUEMKE S,SALMOUKAS C,et al.Bacteriophage therapy for critical infections related to cardiothoracic surgery[J].Antibiotics,2020,9(5):232.
[62] 李莉莎,李建辉,何斌,等.噬菌体治疗泛耐药肺炎克雷伯菌肺部感染的临床应用及效果初探[J].上海交通大学学报(医学版),2021,41(9)：1272-1276.LI L S,LI J H,HE B，et al.Clinical application and effect of phage on the treatment of pulmonary infection by pan-drug resistant Klebsiellapneumoniae[J].Journal of Shanghai Jiaotong University (Medical Science),2021,41(9)：1272-1276.(in Chinese)
[63] CANO E J,CAFLISCH K M,BOLLYKY P L,et al.Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniae infection:Case report and in vitro characterization of anti-biofilm activity[J].Clinical Infectious Diseases,2021,73(1):e144-e151.
[64] DOUB J B,SHISHIDO A,SRIKUMARAN U,et al.Salphage:Salvage bacteriophage therapy for a recalcitrant Klebsiella pneumoniae prosthetic shoulder infection—A case report[J].Acta Orthopaedica,2022,93:756-759.
[65] ESKENAZI A,LOOD C,WUBBOLTS J,et al.Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae[J].Nature Communications,2022,13(1):302.
[66] 钟家琪,周雨非,徐雨林,等.噬菌体治疗肺炎克雷伯菌感染的研究进展[J].微生物学报,2024,64(1):61-75.ZHONG J Q,ZHOU Y F,XU Y L,et al.Research progress on bacteriophage therapy for Klebsiella pneumoniae infections[J].Acta Microbiologica Sinica,2024,64(1):61-75.(in Chinese)